EA4151 Available Through ECOG-ACRIN Cancer Research Group
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

Patient Population
See Section 3.0 for Complete Eligibility Details

Eligibility for Screening (Step 0–Pre-registration):
• Age ≥ 18 and ≤ 70 years
• Must have histologically confirmed mantle cell lymphoma, with cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics/FISH (see protocol for details)
• Enrolling physician must feel the patient is a candidate for autologous stem cell transplantation
• May be about to begin/receiving/have completed induction therapy within 120 days prior to pre-registration to Step 0. No more than 300 days may have passed between the first day of induction therapy and pre-registration
  ◦ For patients that completed induction therapy, re-staging evaluation must show PR/CR; post-induction patients with clinical disease progression are not eligible for pre-registration
  ◦ Up to 2 regimens of chemotherapy are allowed as long as continuous response was ongoing throughout therapy (a PR must be achieved)
• No documented history of CNS involvement by mantle cell lymphoma

Eligibility for Treatment Assignment (Step 1):
• Proliferation rate, using Ki-67/MIB-1 must be documented
• Must have received results from FFPE submission: MRD Indeterminate, or identified unique clonal immunoglobulin DNA sequence and MRD assessment completed
• Must have completed induction therapy within 150 days prior to registration to Step 1 AND no more than 300 days elapsed from the first dose of induction chemo given, until the last day of induction chemo administered
  ◦ Must have received at least 4 cycles; up to 2 regimens allowed as long as continuous response was ongoing
  ◦ ECOG PS 0-2; must have radiologic complete/partial remission (Lugano)
• HIV positive patients must meet criteria per protocol

Treatment Plan
See Section 5.0 for Complete Treatment Details

Patient treatment assignment is as follows:
• Arm A or B: clonal molecular marker identified, blood MRD negative, ≥ 100,000 total nucleated cells analyzed for MRD, complete response (Lugano)
• Arm C: clonal molecular marker identified, blood MRD positive, complete/partial response
• Arm D: clonal molecular marker identified, blood MRD indeterminate, complete/partial response; OR no clonal molecular marker identified; OR clonal molecular marker, blood MRD negative, partial response; OR clonal molecular marker, blood MRD negative, < 100,000 nucleated cells for MRD.

Arm A: HCT; Rituximab maintenance 375 mg/m² IV or Rituxan Hycela 1400 mg/23,400 units SQ (or approved rituximab biosimilar) every 8 wks (+/- 1 wk) x 18 doses (to begin 100-140 days after transplant), Arm B: Rituximab maintenance 375 mg/m² IV or Rituxan Hycela 1400 mg/23,400 units SQ (or approved rituximab biosimilar), every 8 wks (+/- 1 wk) x 18 doses (to begin 40-180 days after completion of induction therapy), Arm C: HCT (Note: blood must be submitted at Day 100 +/- 5 days) post-transplant for MRD assessment); Rituximab maintenance 375 mg/m² IV or Rituxan Hycela 1400 mg/23,400 units SQ (or approved rituximab biosimilar) every 8 wks (+/- 1 wk) x 18 doses (to begin 100-140 days after transplant), Arm D: HCT; Rituximab maintenance 375 mg/m² IV or Rituxan Hycela 1400 mg/23,400 units SQ (or approved rituximab biosimilar) every 8 wks (+/- 1 wk) x 18 doses (to begin 100-140 days after transplant)

Notes (see protocol for details):
• Remission induction therapy is not considered protocol therapy, but it may impact the patient’s eligibility to register to treatment
• HCT will be performed per institutional guidelines; rituximab administration to be managed per standard of care; up to 4 doses of maintenance rituximab may be held due to COVID-19 infection/to facilitate vaccination

Patient Enrollment
All Sites: Oncology Patient Enrollment Network (OPEN) https://open.ctsu.org

Protocol Information

Please Enroll Your Eligible Patients!